innerbuddies gut microbiome testing

Gut Microbiome and Asthma: How Allergies Shape Atopic Inflammation

Asthma isn’t just a matter of airways—it’s also deeply connected to the immune system’s “training ground,” your gut. In many people with asthma, especially those with allergic (atopic) tendencies, the immune response becomes skewed toward inflammation. Emerging microbiome research suggests that the composition and activity of gut bacteria can influence how strongly your immune system reacts to allergens, shaping the intensity of atopic inflammation that contributes to asthma symptoms.

Allergies and the gut microbiome are increasingly recognized as two parts of the same inflammatory conversation. When allergen exposure primes the immune system, signals related to allergy can affect gut barrier function and the gut environment (such as mucus, bile acids, and nutrient availability). In turn, these changes influence which microbes thrive—potentially shifting the balance between bacteria that promote immune tolerance and those associated with more inflammatory signaling.

What’s especially promising is that specific gut microbial patterns are being linked to asthma risk, symptom severity, and immune profiles like Th2/IgE-driven responses. By understanding these gut–lung connections, researchers are exploring whether targeted approaches—like improving fiber intake to support beneficial microbes, considering evidence-based dietary strategies, and learning how to avoid factors that disrupt the microbiome—may help support immune balance and potentially improve prevention and relief for atopic inflammation.

Get Your Gut Microbiome Test for Asthma Insights Get Your Gut Microbiome Test Subscription for Asthma Insights
innerbuddies gut microbiome testing

Asthma

Asthma is a chronic inflammatory disease of the airways marked by wheeze, shortness of breath, chest tightness, and cough, often worsened by allergens, infections, smoke, or cold air. It frequently overlaps with atopic conditions such as allergic rhinitis and eczema, suggesting a shared allergy-prone immune profile. Emerging evidence points to the gut microbiome as an upstream influencer of immune development and airway inflammation, helping explain why asthma is so common and persistent worldwide, affecting hundreds of millions of people.

The gut–lung immune axis works through microbial signals that train T cells and produce short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate, which support anti-inflammatory pathways. When microbial diversity is reduced or SCFA producers decline, anti-inflammatory signaling weakens and airway reactivity can rise, particularly in people with atopic overlap. Asthma-associated microbiome patterns often show lower diversity, fewer SCFA-producing taxa, and higher levels of potentially pro-inflammatory bacteria such as Escherichia/Shigella, Streptococcus, Veillonella, Rothia, and Haemophilus.

Testing the gut microbiome may help explain why asthma severity and trigger sensitivity vary between individuals and can guide personalized, microbiome-supportive nutrition and lifestyle strategies alongside standard asthma care. Tools like InnerBuddies assess gut diversity and composition to inform immune balance and track changes over time, with the aim of promoting calmer immune signaling and potentially better symptom control as part of a holistic approach.

  • Reduced gut microbial diversity and loss of SCFA-producing taxa (Faecalibacterium prausnitzii, Roseburia, Coprococcus, Anaerostipes, Blautia, Ruminococcus bromii, Bifidobacterium, Akkermansia muciniphila) lowers butyrate/propionate/acetate and weakens regulatory T cell (Treg)–mediated anti-inflammatory signaling linked to higher asthma activity.
  • Lower SCFA production shifts immune balance toward Th2/allergic responses, increasing airway hyperresponsiveness in asthma.
  • Elevated pro-inflammatory taxa (Escherichia/Shigella, Streptococcus, Veillonella, Rothia, Haemophilus) correlate with heightened airway inflammation and worse symptoms.
  • Gut barrier disruption due to dysbiosis increases systemic microbial signals that reprogram lung immunity toward pro-inflammatory responses.
  • Gut-lung immune axis: gut microbiome signals train T cells; composition can tilt toward allergy-prone or regulatory profiles, affecting asthma severity and persistence.
  • Environmental exposures (infections, smoke, cold air) perturb gut microbiome and metabolite output, amplifying bronchial hyperresponsiveness.
  • Testing and targeted microbiome-informed nutrition can help restore anti-inflammatory metabolites and barrier function, potentially improving asthma symptom control.
Get Your Gut Microbiome Test for Asthma Insights Get Your Gut Microbiome Test Subscription for Asthma Insights
innerbuddies gut microbiome testing

Allergic / atopic

Asthma is a chronic inflammatory disease of the airways, where immune-driven changes lead to airway narrowing, mucus production, and heightened sensitivity to triggers such as allergens, infections, smoke, and cold air. In many people, asthma overlaps with “atopic” conditions—like allergic rhinitis and eczema—driven by an allergy-prone immune profile. Increasingly, research highlights the gut microbiome as a key upstream influence on how the immune system develops and responds, helping shape whether inflammation tends to become more allergic (atopic) and persistent.

  • Wheezing
  • Shortness of breath
  • Chest tightness
  • Cough (often at night or early morning)
  • Allergic rhinitis symptoms (sneezing, runny or stuffy nose)
Get Your Gut Microbiome Test for Asthma Insights Get Your Gut Microbiome Test Subscription for Asthma Insights
innerbuddies gut microbiome testing

Asthma

This is relevant for people who have been diagnosed with asthma or who experience ongoing airway symptoms such as wheezing, shortness of breath, chest tightness, or nighttime/early-morning cough. It’s especially pertinent if your symptoms flare with common triggers like allergens (pollen, dust), viral infections, smoke, or cold air—suggesting immune-driven inflammation in the airways.

It’s also relevant for individuals with “atopic” overlap—such as allergic rhinitis (sneezing, runny or stuffy nose) and/or eczema—because these conditions often travel together. When asthma appears alongside allergic symptoms, it may reflect a tendency toward a more allergy-prone immune response, where the gut microbiome can be an upstream factor influencing how immune regulation develops and persists over time.

This content is useful for anyone looking for a gut-focused, prevention-leaning perspective on asthma management—particularly those interested in why some people develop persistent inflammation rather than intermittent episodes. If you’ve noticed symptoms since childhood, frequent exacerbations, or difficulty controlling triggers despite standard care, exploring the gut microbiome’s role in immune balance can be relevant to understanding potential contributors to airway sensitivity, mucus production, and long-term inflammation.

Asthma is one of the most common chronic respiratory conditions worldwide, affecting an estimated ~262 million people globally (about 3% of the population). Prevalence varies by region, age, and diagnostic practices, but it is consistently reported as a major cause of recurrent symptoms such as wheezing, shortness of breath, chest tightness, and cough—especially at night or early morning.

In many individuals, asthma commonly overlaps with “atopic” conditions like allergic rhinitis (sneezing and a runny or stuffy nose) and eczema, suggesting a shared allergy-prone immune tendency. This atopic overlap is clinically important because allergic triggers (e.g., allergens) and irritants (e.g., smoke or cold air) can worsen airway inflammation and symptoms, contributing to the burden of disease across populations.

From a gut microbiome perspective, research supports that early-life and ongoing differences in gut microbial communities may influence immune development toward more allergic or persistent inflammatory patterns—mechanistically linking the microbiome to the likelihood and severity of asthma. While microbiome studies do not yet replace population-level statistics, they help explain why asthma can be common and recurrent across diverse populations, particularly in people whose symptoms reflect heightened sensitivity to infections and environmental triggers.

Get Your Gut Microbiome Test for Asthma Insights Get Your Gut Microbiome Test Subscription for Asthma Insights
innerbuddies gut microbiome testing

Gut Microbiome and Asthma: How Allergies Shape Your Atopic Inflammation

Asthma is increasingly understood as more than an isolated lung problem: the immune imbalance that drives chronic airway inflammation is influenced upstream by the gut microbiome. Signals from gut microbes help “train” the developing immune system—shaping whether responses become more allergy-prone (atopic) or more balanced—so differences in microbial diversity and composition may affect how strongly the airways react to common triggers.

Research suggests the gut microbiome can influence airway inflammation through immune pathways such as regulation of T-cells and production of short-chain fatty acids (SCFAs) from microbial fermentation. When the gut ecosystem is less supportive of anti-inflammatory signaling, the immune system may tilt toward heightened sensitivity, which can contribute to the wheezing, chest tightness, and nighttime/early-morning cough typical of asthma—especially in people whose asthma overlaps with allergic rhinitis.

Because asthma often coexists with atopic conditions (like allergic rhinitis and eczema), the “gut–lung” and “gut–immune” connections may help explain why gut microbial patterns correlate with symptom severity and persistence. Triggers such as infections, smoke, and cold air can further shift microbial communities and immune responses, potentially amplifying airway reactivity. Improving gut microbial health through diet and microbiome-supportive strategies is therefore being studied as a way to modulate immune function and help reduce the intensity of asthma symptoms.

Get Your Gut Microbiome Test for Asthma Insights Get Your Gut Microbiome Test Subscription for Asthma Insights
innerbuddies gut microbiome testing

Gut Microbiome and Asthma

  • Immune “training” by gut microbes: microbial signals shape T-cell maturation and differentiation (e.g., balancing pro-allergic vs regulatory responses), which can influence asthma susceptibility and baseline airway reactivity.
  • Short-chain fatty acid (SCFA) production: gut fermentation of dietary fibers generates SCFAs (acetate, propionate, butyrate) that promote anti-inflammatory pathways (including regulatory T cells) and help restrain chronic airway inflammation.
  • Gut barrier integrity and immune signaling: dysbiosis can weaken gut epithelial/barrier function and increase translocation of microbial products, which can skew systemic immunity toward a more inflammatory, asthma-promoting state.
  • Systemic cytokine and immune mediator regulation: gut microbial metabolites can modulate circulating inflammatory markers and signaling networks that affect airway inflammation, symptom severity, and response to triggers.
  • Modulation of IgE/Th2 atopy pathways: certain gut microbial patterns are associated with a stronger or weaker Th2/allergy axis, affecting the likelihood of atopic asthma features (e.g., wheeze, allergic rhinitis comorbidity).
  • Microbiome–lung immune cross-talk (gut–lung axis): immune and metabolic signals originating in the gut can influence distal lung immune cells (e.g., macrophages, dendritic cells), altering how strongly airways respond to allergens and respiratory infections.
  • Influence on response to environmental triggers: factors such as infections, smoke, and cold air can alter gut microbial composition and metabolite output, which may amplify airway inflammation and bronchial hyperresponsiveness.

Asthma is increasingly viewed as a whole-body immune condition, not just a problem confined to the lungs. The gut microbiome helps “train” the developing and regulating immune system by shaping how T cells mature and differentiate. Depending on the composition and function of gut microbes, immune responses may tilt toward a more allergy-prone (Th2/atopic) pattern or toward a more balanced, regulatory profile—affecting baseline airway sensitivity and the likelihood of asthma symptoms, especially in people who also have allergic rhinitis or eczema.

A key mediator of this gut–lung immune influence is microbial fermentation of dietary fiber into short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. SCFAs support anti-inflammatory pathways, including the promotion of regulatory T cells, which help restrain chronic immune activation. When the gut ecosystem is less supportive—such as when diversity is reduced or SCFA-generating bacteria are depleted—anti-inflammatory signaling can weaken, allowing airway inflammation to persist and making wheezing, chest tightness, and cough more likely when the body encounters common triggers.

Beyond immune “training,” gut microbes also affect asthma through gut barrier integrity and systemic signaling. Dysbiosis can impair the intestinal epithelial barrier and increase the release or circulation of microbial products that skew immunity toward a more inflammatory state. These systemic immune and cytokine signals can reach the lungs and alter how airway immune cells (e.g., macrophages and dendritic cells) respond to allergens and infections. Finally, environmental exposures like infections, smoke, and cold air can shift gut microbial communities and metabolite output, which may amplify bronchial hyperresponsiveness and worsen symptom severity.

Get Your Gut Microbiome Test for Asthma Insights Get Your Gut Microbiome Test Subscription for Asthma Insights
innerbuddies gut microbiome testing

Microbial patterns summary

In asthma, gut microbiome patterns often show reduced diversity and a skew toward communities that provide less anti-inflammatory metabolic capacity. Compared with healthier gut ecosystems, many studies report lower abundance of fiber-fermenting taxa that generate short-chain fatty acids (SCFAs), along with altered overall community structure that can favor a more pro-inflammatory immune tone. This “less supportive” microbial environment may weaken regulatory pathways that normally restrain airway inflammation, helping explain why some people experience more frequent wheezing, cough, and chest tightness when exposed to common triggers.

A recurring feature linked to asthma severity is variation in SCFA-related fermentation. When SCFA-producing bacteria are depleted, levels of metabolites such as butyrate, acetate, and propionate may fall, reducing support for regulatory T-cell development and maintenance. Without adequate SCFA signaling, immune responses can tilt toward an allergy-prone pattern (often associated with Th2/atopic biology), which is especially relevant in asthma that co-occurs with allergic rhinitis or eczema. Microbial patterns that correlate with diminished barrier-supporting activity can also contribute, since impaired gut-epithelial integrity may increase systemic exposure to inflammatory microbial products.

Asthma-associated microbial signatures are also shaped by the host’s environment and exposures that indirectly act through the gut. Shifts caused by respiratory infections, air pollutants or smoke, and dietary changes can remodel gut communities and metabolite output, potentially amplifying systemic cytokine signaling that reaches the lungs. Across these contexts, dysbiosis-related immune activation—along with altered antigen presentation and heightened airway immune responsiveness—can contribute to bronchial hyperreactivity. Overall, the gut–lung immune axis is reflected in microbiome patterns that balance tolerance (through SCFAs and barrier integrity) versus inflammation (through dysbiosis and pro-inflammatory systemic signals).


Low beneficial taxa

  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Coprococcus spp.
  • Anaerostipes spp.
  • Blautia spp.
  • Ruminococcus bromii
  • Bifidobacterium spp.
  • Akkermansia muciniphila


Elevated / overrepresented taxa

  • Escherichia/Shigella
  • Streptococcus
  • Veillonella
  • Rothia
  • Haemophilus


Functional pathways involved

  • Short-chain fatty acid (SCFA) production via fiber fermentation (butyrate/propionate/acetate biosynthesis)
  • Bile acid metabolism and bile-acid–mediated immune modulation (including FXR/TGR5 signaling effects)
  • Regulation of regulatory T-cell (Treg) differentiation through SCFA signaling (e.g., butyrate-driven epigenetic modulation)
  • Intestinal epithelial barrier support and mucin/biopolymer utilization (including mucin-degradation balance and mucus integrity)
  • Microbial-derived lipopolysaccharide (LPS) and other pro-inflammatory metabolite generation affecting systemic cytokine tone
  • Microbial modulation of tryptophan metabolism (indole/aryl hydrocarbon receptor pathways) that influences airway immune responses
  • Pattern recognition receptor (PRR) and toll-like receptor (TLR) stimulation capacity from dysbiotic taxa/metabolites
  • Bacterial carbohydrate fermentation pathways that shape gut ecological balance and downstream immune signaling


Diversity note

In people with asthma, studies commonly find a gut microbiome with reduced overall diversity compared with healthier controls. This loss of microbial variety often reflects a shift away from communities that generate anti-inflammatory metabolites, which can weaken the immune “tolerance” signals that help keep airway inflammation in check. As a result, the gut ecosystem may become less supportive of regulatory immune pathways, contributing to greater susceptibility to wheezing, cough, and chest tightness when exposed to common triggers.

A recurring theme is diminished abundance of fiber-fermenting bacteria that produce short-chain fatty acids (SCFAs) such as butyrate, acetate, and propionate. When these SCFA-producing groups are less prevalent, the gut’s metabolic output tends to shift, which may reduce support for regulatory T-cell development and maintenance. This can help tilt immune responses toward a more allergy-prone, Th2/atopic pattern—particularly in individuals whose asthma overlaps with allergic rhinitis or eczema—thereby potentially increasing symptom persistence or severity.

Microbial diversity and composition in asthma are also shaped by factors that act upstream of the gut, including diet changes, respiratory infections, air pollutants, and smoke exposure. These influences can further remodel gut communities and alter metabolite production, which may amplify systemic immune signaling that can reach the lungs. Overall, the typical diversity pattern in asthma points to a gut environment that is less capable of producing anti-inflammatory, barrier-supporting signals and more likely to favor pro-inflammatory immune tone.


Get Your Gut Microbiome Test for Asthma Insights Get Your Gut Microbiome Test Subscription for Asthma Insights

Why generic solutions fail

  • Issue with generic solutions

    Generic approaches often fail in asthma because the “gut–lung” connection is not driven by a single deficiency or one universally beneficial microbe. Many people have asthma rooted in distinct immune patterns—ranging from more Th2/atopic inflammation (common with allergic rhinitis or eczema) to non-allergic or infection-triggered phenotypes—so the gut microbiome signal they need to modulate is phenotype-specific. If a broad intervention doesn’t address the underlying immune skew, it may not restore the regulatory pathways (especially those supported by microbial metabolites like SCFAs) that help restrain airway inflammation.

    They also fail because gut microbiome problems in asthma are frequently about ecological balance and metabolic output, not just overall “diversity.” Standard probiotics or one-size-fits-all prebiotics can introduce or stimulate organisms without ensuring the right fermentation capacity, substrate availability, or host conditions for sustained SCFA production. In practice, some individuals may need fiber types that feed particular fermentation pathways, while others have barrier-related or inflammatory constraints that blunt microbial metabolite benefits—so generic products can lead to minimal or inconsistent SCFA and T-cell regulatory effects.

    Finally, asthma is strongly influenced by exposures that can continuously remix the gut ecosystem, such as respiratory infections, smoke/air pollution, dietary swings, and even medication effects. Without tailoring to these drivers, an intervention may provide short-term microbiome changes that don’t persist long enough to measurably change airway reactivity. Because dysbiosis-linked immune activation can be downstream of multiple upstream factors, generic solutions that ignore personal context—dietary pattern, allergen burden, comorbidities, and exposure history—tend to underperform even when they improve some gut markers.

  • Common mistakes

    • Treating asthma as one microbiome problem—using the same intervention for different asthma phenotypes (Th2/atopic vs non-allergic/infection-triggered), even though the gut–lung immune “skew” is not uniform.
    • Optimizing for generic “increased diversity” instead of functional outcomes (e.g., SCFA/short-chain fatty acid fermentation capacity, butyrate/propionate/acetate output, and epithelial-supporting metabolites).
    • Using standard probiotics without ensuring strain-level relevance to SCFA production or without accounting for whether the host gut environment can sustain engraftment and the intended fermentation pathways.
    • Prescribing one-size-fits-all prebiotics/fiber without matching fiber type to the fermentation deficits that matter for the person (substrate availability, tolerance to specific fibers, and the risk of inadequate or misdirected fermentation).
    • Ignoring the role of ongoing exposures that continuously remix the gut ecosystem—respiratory infections, smoke/air pollutants, dietary swings, and medication effects—so microbiome changes don’t persist or can’t translate to airway improvements.
    • Overlooking comorbidities and immune context (allergic rhinitis, eczema, food allergy pattern, obesity, reflux), which can change the gut–immune signaling targets and blunt response to generic gut interventions.
    • Failing to account for dysbiosis that affects barrier integrity, not just immune signaling—missing opportunities to address epithelial-supporting conditions that influence systemic inflammatory signaling to the lungs.
    • Expecting short-term microbiome improvements to rapidly reduce bronchial hyperreactivity—without enough time, dose, and consistency to shift regulatory pathways (e.g., Treg maintenance) that depend on sustained metabolite signaling.

What to do

  • General support strategies

    For asthma support through the gut–lung axis, the goal is to foster a gut environment that supports anti-inflammatory immune signaling. Diet patterns that increase microbial diversity and promote beneficial fermentation can help generate short-chain fatty acids (SCFAs), which play a role in regulating T-cell balance and dampening excessive airway inflammation. In practice, this often means emphasizing a fiber-rich diet (such as fruits, vegetables, legumes, whole grains, and other plant foods) while limiting highly processed foods that may reduce microbial diversity and encourage inflammation.

    Supporting gut microbial stability can also involve targeted “microbiome food” strategies, such as adequate intake of prebiotic fibers and, for some people, carefully selected fermented foods (e.g., yogurt or kefir) to introduce beneficial microbes or metabolic byproducts. Hydration, regular meal timing, and avoiding unnecessary antibiotic exposure when possible may further help preserve a healthy microbial ecosystem, especially during periods when infections or other asthma triggers are more common. Because asthma frequently overlaps with atopic conditions like allergic rhinitis, creating a gut environment that promotes immune tolerance may be particularly relevant for those whose symptoms flare with allergens.

    It’s also important to recognize that the gut microbiome responds to the same real-world factors that affect asthma—airway infections, smoke exposure, and cold weather can shift immune tone and may indirectly influence gut communities as well. Therefore, microbiome-supportive habits should be viewed as complementary to standard asthma management, not a replacement for inhaled therapies. Consistency is key: gradual dietary and lifestyle changes, stress management, and maintaining overall metabolic health can support a more resilient immune system over time and may help reduce symptom intensity and persistence in susceptible individuals.

  • Lifestyle recommendations

    • Aim for a fiber-rich, diverse diet (e.g., fruits, vegetables, legumes, whole grains) to support a healthier gut microbiome and anti-inflammatory immune signaling.
    • Include prebiotic/probiotic-friendly foods regularly (e.g., yogurt/kefir with live cultures, fermented foods like kimchi/sauerkraut, and high-fiber foods) if tolerated.
    • Maintain a healthy body weight and engage in regular moderate exercise (asthma-controlled activity), since obesity can worsen airway inflammation.
    • Minimize known asthma triggers (e.g., tobacco smoke, strong odors, pollution exposure) and reduce respiratory infections with good hygiene and recommended vaccinations.
    • During treatment, take medications as prescribed and avoid unnecessary antibiotics, since they can disrupt gut microbial balance.

  • Nutrition recommendations

    • Aim for a high-fiber, plant-forward diet (e.g., legumes, lentils, beans, oats, fruits, vegetables) to support microbial diversity and increase production of short-chain fatty acids (SCFAs) that help regulate airway immune responses.
    • Prioritize prebiotic foods and gentle fermentables (e.g., onions, garlic, leeks, asparagus, bananas—especially slightly underripe—oats, and cooked-then-cooled potatoes/rice) to feed beneficial gut bacteria involved in anti-inflammatory signaling.
    • Include omega-3 rich foods 2–3x/week (fatty fish like salmon/sardines, or algae-based omega-3) to support more balanced inflammatory pathways and potentially reduce airway inflammation severity.
    • Choose probiotic-rich foods regularly if tolerated (e.g., yogurt with live cultures, kefir, kimchi, sauerkraut, tempeh) to help support a healthier gut microbial ecosystem.
    • Reduce ultra-processed foods and added sugars, since these can promote dysbiosis and may worsen inflammatory tone and asthma control in some people.
    • Consider a consistent, diverse carbohydrate pattern rather than highly restrictive diets; abrupt elimination of many fiber sources can reduce microbial diversity that supports immune training.
    • If your asthma is triggered by reflux or GI symptoms, optimize meal timing and composition (smaller meals, avoid late-night eating, reduce very fatty/spicy foods) to limit gut-immune stress signals that can indirectly affect airway symptoms.

  • Supplement considerations

    For asthma, supplement strategies are increasingly framed around the gut–immune connection rather than treating the lungs in isolation. The gut microbiome can help “train” immune responses, influencing whether inflammation becomes more allergy-prone (atopic) or more balanced. When gut microbial diversity or beneficial metabolite production is reduced, immune signaling may tilt toward heightened airway reactivity, potentially worsening wheezing, chest tightness, and cough—particularly in people with asthma that overlaps with allergic rhinitis or other atopic conditions.

    Several supplement categories are being studied for their potential to support anti-inflammatory immune pathways. Probiotics (and, in some cases, targeted multi-strain formulas) may help modulate T-cell activity and inflammatory tone, while prebiotics such as fermentable fibers can increase production of short-chain fatty acids (SCFAs). SCFAs generated in the colon are of interest because they can influence immune regulation and barrier function, which may indirectly affect how strongly the airways respond to common triggers. Some individuals also explore postbiotics (microbial metabolites or cell components) as a gentler approach that bypasses live-organism variability.

    Because asthma is also impacted by environmental triggers—such as respiratory infections, smoke exposure, and cold air—supplement choices should be viewed as adjuncts to established care rather than replacements. It’s also important to consider individual factors like existing diet, recent antibiotic use, and personal atopy risk when selecting a strain/format or fermentation-targeting approach. As responses can vary widely by person, a cautious, stepwise trial with attention to symptom changes and tolerability is typically more practical than “one-size-fits-all” supplementation.

  • Retesting / monitoring note

    For asthma, retesting is generally considered when symptoms change, when treatment response is unclear, or when there’s a need to refine the underlying driver of inflammation. Because asthma severity and control are influenced by immune status—including gut–lung immune signaling—retesting may be timed around periods of clinical change (for example, after an exacerbation, a medication adjustment, or a sustained improvement/worsening over several weeks). It can also be appropriate to reassess if there is overlap with allergic conditions (such as allergic rhinitis or eczema), since immune patterns linked to atopy often evolve and can affect how strongly airways respond to common triggers.

    When retesting involves microbiome-related assessments, the goal is usually to confirm whether a prior gut microbial profile has shifted in a clinically meaningful direction and whether that change aligns with symptom trends. Because gut microbial composition can respond to factors like diet, infections, stress, antibiotics, smoke exposure, and seasonal variation, retesting is typically best done after enough time for meaningful community stabilization—often after medication changes and major exposures have resolved—so results reflect longer-term patterns rather than short-term noise. Consistent preparation (same diet style, sampling method, and timing relative to antibiotics/illness) improves interpretability and reduces the chance of misleading conclusions.

    In practice, retesting should be coordinated with routine asthma monitoring (symptom scores, rescue inhaler use, lung function when applicable) to determine whether immune and microbial markers add actionable information. If microbiome-supportive strategies are being trialed—such as dietary fiber-focused approaches that increase SCFA production and promote anti-inflammatory immune signaling—retesting can help determine whether improvements in gut ecosystem indicators parallel better asthma control. Conversely, if symptoms persist despite optimized standard care, retesting may help identify additional contributors (such as ongoing dysbiosis drivers or uncontrolled atopic inflammation) that warrant a revised plan.

The importance of gut microbiome testing

  • Why testing matters

    Asthma is driven by chronic immune signaling in the airways, and emerging evidence shows that the gut microbiome can influence that signaling “upstream.” Gut microbes help shape immune development and balance—impacting how strongly the body’s T-cell responses and allergic pathways are activated. Because these immune effects can vary by person, gut microbiome testing may help explain why asthma severity, persistence, and trigger sensitivity differ between individuals, even when they share similar environmental exposures.

    Testing can also be relevant for identifying microbial patterns associated with less anti-inflammatory signaling. For example, gut bacteria that produce short-chain fatty acids (SCFAs) via fermentation can support regulatory immune pathways, which may calm airway inflammation. When the gut ecosystem is less supportive of these protective metabolites, asthma may be more reactive, particularly in people with overlapping atopic conditions like allergic rhinitis. By measuring diversity and composition, testing can provide clues about whether someone’s gut environment may be contributing to immune imbalance.

    Finally, gut microbiome results can guide more personalized, microbiome-supportive nutrition or lifestyle strategies that are being explored as adjuncts to conventional asthma care. Since factors like infections, smoke exposure, stress, diet, and even seasonal changes can shift gut communities, baseline testing followed by targeted follow-up may help track whether interventions are helping restore a gut profile linked with more balanced immune responses—potentially supporting better symptom control and reducing the intensity of wheezing, chest tightness, and cough.

  • How InnerBuddies helps

    InnerBuddies can help for asthma by looking at gut microbial diversity and composition—because the gut microbiome is increasingly recognized as a key “upstream” influence on the immune pathways that drive chronic airway inflammation. Gut microbes help shape immune development and balance, including how strongly T-cells and allergic (atopic) responses are activated. When the gut ecosystem is less supportive of anti-inflammatory immune signaling, airway reactivity may be higher, which can make wheezing, chest tightness, and nighttime/early-morning cough more likely in response to everyday triggers.

    By highlighting microbial patterns associated with lower production of protective metabolites (such as short-chain fatty acids, or SCFAs), InnerBuddies may provide insight into whether your gut environment could be contributing to a more pro-inflammatory immune tilt. This is especially relevant for people whose asthma overlaps with atopic conditions like allergic rhinitis, where immune sensitivity can be more pronounced. The test results can therefore help explain why asthma severity and persistence vary from person to person even with similar environmental exposures.

    Finally, InnerBuddies can support more personalized, microbiome-informed nutrition and lifestyle strategies that may complement standard asthma care. Because diet, infections, smoke exposure, stress, and seasonal changes can shift the gut microbiome, using test results as a baseline (and potentially for follow-up) can help track whether interventions are moving the gut profile toward a more anti-inflammatory direction—aiming to support calmer immune signaling and potentially improved symptom control over time.

Medical Evidence

  • Scientific evidence level

    2 [weak (emerging but inconsistent)]

  • Clinical relevance note

    Current clinical relevance (association and potential prediction) is limited. While multiple studies report statistical associations between gut microbiome characteristics and asthma status or risk, the lack of reproducible microbial signatures, methodological inconsistency (sequencing platforms, pipelines, reference databases), and substantial confounding and reverse causality mean these findings are not yet reliable for individual risk prediction or phenotype stratification in routine care. Biomarker-like approaches exist in research settings, but they have not achieved widely replicated, externally validated thresholds or demonstrated added value over established clinical predictors (family history, early-life wheeze, atopy, lung function).

    For intervention, microbiome modulation is not yet an evidence-based treatment for asthma. RCTs are relatively few, vary in formulation/dosing/timing, and often use endpoints that do not clearly map to hard clinical outcomes such as exacerbation reduction, steroid-sparing effects, or sustained improvement in lung function. Therefore, microbiome-targeted interventions should not be considered clinically actionable specifically for asthma based on the current strength of evidence. The strongest role today is hypothesis generation and refinement of mechanistic pathways, with future work needed for well-powered prospective cohorts, standardized microbiome methodology, careful treatment/confounder control, causal inference (including stronger causal designs), and RCTs targeting clearly defined phenotypes and clinically meaningful endpoints.

Title Journal Year Link
Microbiome and childhood asthma: an updated systematic review and meta-analysis The Lancet Respiratory Medicine 2023 View →
The gut microbiome and asthma: a systematic review of evidence and mechanisms European Respiratory Review 2018 View →
Gut microbiota influences immune maturation and induces protection against experimental asthma through induction of regulatory T cells Nature Communications 2017 View →
Asthma is associated with altered gut microbiota and gut barrier function Journal of Allergy and Clinical Immunology 2016 View →
Early-life gut microbiota and risk of childhood asthma Clinical & Experimental Allergy 2014 View →

Frequently Asked Questions

    ¿Cuál es la conexión intestino–pulmón en el asma?
    La idea es que los microbios intestinales y sus metabolitos pueden influir en respuestas inmunes que afectan las vías respiratorias; no es una causa directa para todas las personas.
    ¿Cómo podría el microbioma intestinal influir en los síntomas del asma?
    A través del entrenamiento inmunológico, la producción de SCFA y la integridad de la barrera intestinal; cambios en el microbioma pueden estar relacionados con una mayor sensibilidad de las vías respiratorias.
    ¿Qué son los SCFA y por qué son importantes?
    Ácidos grasos de cadena corta (acetato, propionato, butirato) producidos al fermentar fibra; ayudan a regular la inflamación y apoyan las células T reguladoras.
    ¿La prueba del microbioma puede ayudar a manejar el asma?
    Puede aportar ideas sobre diversidad y metabolismo, pero no sustituye la atención estándar ni es un diagnóstico.
    ¿Qué bacterias intestinales son buenas o malas para el asma?
    Buenas: Faecalibacterium prausnitzii, Roseburia, Coprococcus, Anaerostipes, Blautia, Ruminococcus bromii, Bifidobacterium, Akkermansia muciniphila. Elevadas: Escherichia/Shigella, Streptococcus, Veillonella, Rothia, Haemophilus.
    Si mi asma coexiste con rinitis alérgica, ¿significa esto que mi microbioma está involucrado?
    Puede haber solapamiento en vías inmunológicas; el microbioma puede ayudar a explicar por qué los síntomas aparecen juntos; es complejo e individual.
    ¿Cómo puedo apoyar un microbioma intestinal más saludable?
    Dieta variada y rica en fibra; reducir azúcares añadidos; uso prudente de antibióticos; actividad física regular.
    ¿Existen cambios en la dieta que podrían influir en el asma a través del intestino?
    La alimentación puede afectar el microbioma y la producción de SCFA; las dietas ricas en fibra apoyan señales antiinflamatorias; las respuestas varían.
    ¿Qué papel juegan factores ambientales como el humo y las infecciones en el microbioma y el asma?
    Pueden cambiar las comunidades intestinales y los metabolitos, aumentando potencialmente la inflamación de las vías aéreas.
    ¿Qué mide la prueba InnerBuddies y cómo interpretar los resultados?
    Mide la diversidad y la composición del microbioma; los resultados deben discutirse con un profesional de la salud; no son un diagnóstico.
    ¿La prueba puede reemplazar la atención estándar del asma?
    No; es una herramienta informativa que complementa, no reemplaza, los tratamientos convencionales.
    ¿Dónde puedo encontrar información fiable o cómo hablar con mi médico?
    Busque fuentes médicas fiables y hable con su proveedor de atención de la salud sobre pruebas del microbioma y el asma.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -